Dupilumab use in asthma is linked to higher lymphoma risk, especially T and NK cell types, but also shows reduced all-cause ...

Dupilumab was approved by the FDA to treat bullous pemphigoid, that demonstrated its efficacy in achieving sustained disease ...

The US Food and Drug Administration (FDA) has approved dupilumab for the treatment of chronic spontaneous urticaria (CSU) in patients aged 12 years and older who “remain symptomatic despite H1 ...

This thesis explores two strategies to improve monoclonal antibody (mAb) production in CHO cells: multivariate data analysis (MVDA) with spectroscopic data and the use of chemical additives. MVDA with ...

Chinese hamster ovary (CHO) cells are the cornerstone of biopharmaceutical production, accounting for 70% of all approved recombinant protein production. These immortalized cells offer high ...

The phase III LIBERTY-CUPID study C showed that among children and adults randomized to receive either dupilumab or placebo added to standard-of-care (SoC) H1 antihistamines, those receiving ...

Take a deep dive into their recent study to learn more about High-Intensity Perfusion CHO Medium. We explore how it supports extremely high cell densities, and why it leads to enhanced ...

Dupilumab-treated patients with AD were 4.1003 times more likely to develop cutaneous T-cell lymphoma vs. those who were not dupilumab-treated. Most cases were diagnosed more than 1 year after ...

DUBLIN , Nov. 20, 2023 /PRNewswire/ -- The "Dupilumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering. This report offers comprehensive ...